Understanding the Omicron Variant Impact in Healthcare Workers: Insights from the Prospective COVID-19 Post-Immunization Serological Cohort in Munich (KoCo-Impf) on Risk Factors for Breakthrough and Reinfections
Christian Janke,
Raquel Rubio-Acero,
Maximilian Weigert,
Christina Reinkemeyer,
Yeganeh Khazaei,
Lisa Kleinlein,
Ronan Le Gleut,
Katja Radon,
Marlene Hannes,
Francesco Picasso,
Anne Elisabeth Lucke,
Michael Plank,
Irene Charlotte Kotta,
Ivana Paunovic,
Ana Zhelyazkova,
Ivan Noreña,
Simon Winter,
Michael Hoelscher,
Andreas Wieser,
Helmut Küchenhoff,
Noemi Castelletti,
on behalf of the ORCHESTRA Working Group
Affiliations
Christian Janke
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Raquel Rubio-Acero
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Maximilian Weigert
Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany
Christina Reinkemeyer
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Yeganeh Khazaei
Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany
Lisa Kleinlein
Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany
Ronan Le Gleut
Institute of Computational Biology, Helmholtz Munich, 85764 Neuherberg, Germany
Katja Radon
Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, LMU University Hospital, LMU Munich, 80336 Munich, Germany
Marlene Hannes
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Francesco Picasso
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Anne Elisabeth Lucke
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Michael Plank
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Irene Charlotte Kotta
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Ivana Paunovic
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Ana Zhelyazkova
Institut für Notfallmedizin und Medizinmanagement (INM), LMU Klinikum, LMU München, 80336 Munich, Germany
Ivan Noreña
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Simon Winter
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Michael Hoelscher
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Andreas Wieser
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
Helmut Küchenhoff
Statistical Consulting Unit StaBLab, Department of Statistics, LMU Munich, 80539 Munich, Germany
Noemi Castelletti
Institute of Infectious Diseases and Tropical Medicine, LMU University Hospital, LMU Munich, 80802 Munich, Germany
This study analyzes immune responses to SARS-CoV-2 vaccination and infection, including asymptomatic cases, focusing on infection risks during the Omicron wave, particularly among high-risk healthcare workers. In the KoCo-Impf study, we monitored 6088 vaccinated participants in Munich aged 18 and above. From 13 May to 31 July 2022, 2351 participants were follow-uped. Logistic regression models evaluated primary, secondary, and breakthrough infections (BTIs). Roche Elecsys® Anti-SARS-CoV-2 assays detected prior infections (via anti-Nucleocapsid antibodies) and assessed vaccination/infection impact (via anti-Spike antibodies) using dried blood spots. Our findings revealed an anti-Nucleocapsid seroprevalence of 44.1%. BTIs occurred in 38.8% of participants, with reinfections in 48.0%. Follow-up participation was inversely associated with current smoking and non-vaccination, while significantly increasing with age and receipt of three vaccine doses. Larger household sizes and younger age increased infection risks, whereas multiple vaccinations and older age reduced them. Household size and specific institutional subgroups were risk factors for BTIs. The anti-Nucleocapsid value prior to the second infection was significantly associated with reinfection risk. Institutional subgroups influenced all models, underscoring the importance of tailored outbreak responses. The KoCo-Impf study underscores the importance of vaccination, demographic factors, and institutional settings in understanding SARS-CoV-2 infection risks during the Omicron wave.